Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Latest Posted May 30, 2024
Young Living Essential Oils Agrees to Pay $5 Million to Settle Lawsuit
Young Living Essential Oils has agreed to pay up to $5 million to settle a class action lawsuit that charged the company with promoting its essential oils to reduce stress and anxiety, improve sleep, and other health-related claims without reliable scientific evidence.
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
Other Recent Recalls & Warnings
Company Stopped by FTC from Claiming to Prevent or Reverse Memory Loss without Evidence
July 15, 2004
FTC Challenges Deceptive Weight Loss Claims for Supplement Targeted at Hispanics
June 17, 2004
FTC Challenges Ads for Kids’ Weight Loss Pill and Female Sexuality Supplement
June 16, 2004
Ads for Various Diet Pills and Topical Gels Don’t Cut the Fat, Says the FTC
June 16, 2004
FTC Charges Marketers of Two Supplements with False Claims to Cure Range of Diseases
June 04, 2004
Makers of Fat and Starch "Blockers" Receive FDA Warning Letters
April 02, 2004
Aloe Producer Recalls Product Due to Toxic Levels of Vitamin D
April 01, 2004
Seasilver Stopped from Making Claim to Cure "Over 650" Diseases
March 19, 2004
Marketers of “Focus Factor” and “V-Factor” Fined for Advertising Claims
March 17, 2004
FTC Stops False Advertising by Makers of Weight Loss and Arthritis “Cures”
March 09, 2004
For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please visit the FDA MedWatch website.